JP2017503014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503014A5 JP2017503014A5 JP2016559686A JP2016559686A JP2017503014A5 JP 2017503014 A5 JP2017503014 A5 JP 2017503014A5 JP 2016559686 A JP2016559686 A JP 2016559686A JP 2016559686 A JP2016559686 A JP 2016559686A JP 2017503014 A5 JP2017503014 A5 JP 2017503014A5
- Authority
- JP
- Japan
- Prior art keywords
- lag
- protein
- preparation according
- combination preparation
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000017578 LAG3 Human genes 0.000 claims description 38
- 101150030213 Lag3 gene Proteins 0.000 claims description 38
- 229940034982 antineoplastic agent Drugs 0.000 claims description 29
- 239000002246 antineoplastic agent Substances 0.000 claims description 29
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 16
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 8
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229910052697 platinum Inorganic materials 0.000 claims description 8
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims description 3
- 229940056913 eftilagimod alfa Drugs 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000011260 co-administration Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108020001580 protein domains Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322626.1 | 2013-12-19 | ||
| GBGB1322626.1A GB201322626D0 (en) | 2013-12-19 | 2013-12-19 | Combined preparations for the treatment of cancer |
| PCT/EP2014/078779 WO2015091970A1 (en) | 2013-12-19 | 2014-12-19 | Combined preparations for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019163672A Division JP7160345B2 (ja) | 2013-12-19 | 2019-09-09 | がんの治療のための組合せ調製物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503014A JP2017503014A (ja) | 2017-01-26 |
| JP2017503014A5 true JP2017503014A5 (enExample) | 2018-02-01 |
| JP6691054B2 JP6691054B2 (ja) | 2020-05-20 |
Family
ID=50071175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559686A Active JP6691054B2 (ja) | 2013-12-19 | 2014-12-19 | がんの治療のための組合せ調製物 |
| JP2019163672A Active JP7160345B2 (ja) | 2013-12-19 | 2019-09-09 | がんの治療のための組合せ調製物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019163672A Active JP7160345B2 (ja) | 2013-12-19 | 2019-09-09 | がんの治療のための組合せ調製物 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10736940B2 (enExample) |
| EP (3) | EP3511004B1 (enExample) |
| JP (2) | JP6691054B2 (enExample) |
| KR (3) | KR102441425B1 (enExample) |
| CN (2) | CN112957452A (enExample) |
| AU (1) | AU2014368420B2 (enExample) |
| DK (2) | DK3089749T3 (enExample) |
| ES (2) | ES2986949T3 (enExample) |
| FI (1) | FI3511004T3 (enExample) |
| GB (1) | GB201322626D0 (enExample) |
| PL (2) | PL3511004T3 (enExample) |
| PT (2) | PT3511004T (enExample) |
| TR (1) | TR201910866T4 (enExample) |
| WO (1) | WO2015091970A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| US10265379B2 (en) * | 2015-09-16 | 2019-04-23 | Annabelle Rodriguez Oquendo | Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| KR20180086502A (ko) | 2015-12-16 | 2018-07-31 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항원-결합 단편 |
| CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| WO2021242876A1 (en) * | 2020-05-27 | 2021-12-02 | Agilent Technologies, Inc. | Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc) |
| US20230210946A1 (en) * | 2020-05-28 | 2023-07-06 | Immutep S.A.S. | Treatment of cancer |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5098702A (en) | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| CA1341281C (en) | 1986-07-09 | 2001-08-07 | Hubert J.P. Schoemaker | Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| CA1339354C (en) | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| NZ232562A (en) | 1989-02-17 | 1992-10-28 | Coselco Mimotopes Pty Ltd | Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support |
| JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規ｄｎａならびにそれを含有する発現プラスミド |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| US7294712B2 (en) | 1990-06-04 | 2007-11-13 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| DK0551401T3 (da) | 1990-09-14 | 1996-01-22 | Univ Texas | Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet |
| JP3459268B2 (ja) * | 1990-09-17 | 2003-10-20 | 中外製薬株式会社 | 抗癌剤 |
| US6596536B1 (en) | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| EP1721978B1 (fr) | 1991-02-08 | 2011-04-06 | Aventis Pharma S.A. | Séquences nucléotidiques codant pour des régions variables de chaines alpha des récepteurs des lymphocytes humains ainsi que leurs applications |
| JPH06502997A (ja) | 1991-02-12 | 1994-04-07 | ルセル ユクラフ | ヒトＴリンパ球レセプターのβ鎖の可変領域をコードするヌクレオチド配列対応するペプチドセグメント並びに診断及び治療への利用 |
| US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US6506604B2 (en) | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| IL113617A (en) | 1994-05-06 | 2007-09-20 | Florence Faure | Use of LAG-3 antibodies to prepare a therapeutic agent that stimulates the immune system |
| US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| JP2000516101A (ja) | 1996-11-28 | 2000-12-05 | アンスティテュ ギュスタブ ルシ | Ｌａｇ−３タンパク質の変異体、その発現及び使用 |
| EP0941329B1 (en) | 1996-11-29 | 2004-07-21 | Applied Research Systems ARS Holding N.V. | Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3) |
| WO1998046728A1 (en) | 1997-04-14 | 1998-10-22 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant aav product |
| EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| US6037177A (en) | 1997-08-08 | 2000-03-14 | Cell Genesys, Inc. | Method for increasing the efficiency of recombinant AAV production |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CA2318372C (en) | 1998-02-02 | 2008-08-19 | Johns Hopkins University School Of Medicine | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
| FR2777890B1 (fr) | 1998-04-22 | 2000-12-29 | Roussy Inst Gustave | Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer |
| AU5458500A (en) | 1999-06-02 | 2000-12-18 | Cell Genesys, Inc. | Regulation of systemic immune responses utilizing cytokines and antigens |
| FR2795415B1 (fr) | 1999-06-28 | 2003-09-05 | Roussy Inst Gustave | Compose peptidique derive d'une orf decalee du gene ice |
| AT409086B (de) | 1999-11-16 | 2002-05-27 | Igeneon Krebs Immuntherapie | Neue verwendung von antikörpern als impfstoffe |
| CA2406949A1 (fr) | 2000-04-26 | 2001-11-01 | Roger Kravtzoff | Utilisation de vecteurs particulaires dans l'immunomodulation |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| EP1295895B1 (en) | 2001-09-19 | 2011-08-10 | Institut Gustave Roussy | Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof |
| DK1505973T3 (da) | 2002-05-17 | 2010-05-31 | Celgene Corp | Kombinationer til behandling af multipelt myelom |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| NZ547042A (en) | 2003-10-10 | 2010-05-28 | Powderject Vaccines Inc | Method for eliciting a T-cell response |
| FR2868781B1 (fr) | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
| JP2006124383A (ja) | 2004-09-30 | 2006-05-18 | Kobayashi Pharmaceut Co Ltd | 樹状細胞活性化剤 |
| JP2006141346A (ja) | 2004-11-24 | 2006-06-08 | Kobayashi Pharmaceut Co Ltd | 樹状細胞活性化剤 |
| US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| US20070231298A1 (en) | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| US8425897B2 (en) | 2007-08-30 | 2013-04-23 | Immutep S.A. | Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use |
| EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CN103347521B (zh) * | 2010-12-06 | 2018-05-25 | 全球癌症治疗有限责任公司 | 用于治疗癌症的使用化疗和免疫治疗的代谢靶向癌细胞的方法 |
| PL2691112T3 (pl) | 2011-03-31 | 2018-09-28 | Merck Sharp & Dohme Corp. | Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane |
| RU2014111999A (ru) | 2012-02-01 | 2016-03-27 | Компуджен Лтд. | Антитела к C10RF32 и их применения для лечения рака |
| KR102418979B1 (ko) | 2012-05-15 | 2022-07-11 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| EA036902B1 (ru) | 2013-09-20 | 2021-01-13 | Бристол-Майерс Сквибб Компани | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2015131176A1 (en) | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
-
2013
- 2013-12-19 GB GBGB1322626.1A patent/GB201322626D0/en not_active Ceased
-
2014
- 2014-12-19 DK DK14830806.7T patent/DK3089749T3/da active
- 2014-12-19 PL PL19158672.6T patent/PL3511004T3/pl unknown
- 2014-12-19 KR KR1020227014127A patent/KR102441425B1/ko active Active
- 2014-12-19 ES ES19158672T patent/ES2986949T3/es active Active
- 2014-12-19 AU AU2014368420A patent/AU2014368420B2/en active Active
- 2014-12-19 ES ES14830806T patent/ES2730976T3/es active Active
- 2014-12-19 EP EP19158672.6A patent/EP3511004B1/en active Active
- 2014-12-19 PT PT191586726T patent/PT3511004T/pt unknown
- 2014-12-19 US US15/105,789 patent/US10736940B2/en active Active
- 2014-12-19 WO PCT/EP2014/078779 patent/WO2015091970A1/en not_active Ceased
- 2014-12-19 PT PT14830806T patent/PT3089749T/pt unknown
- 2014-12-19 DK DK19158672.6T patent/DK3511004T3/da active
- 2014-12-19 KR KR1020227025903A patent/KR102593917B1/ko active Active
- 2014-12-19 JP JP2016559686A patent/JP6691054B2/ja active Active
- 2014-12-19 KR KR1020167019272A patent/KR20160093076A/ko not_active Ceased
- 2014-12-19 CN CN202110293412.9A patent/CN112957452A/zh active Pending
- 2014-12-19 FI FIEP19158672.6T patent/FI3511004T3/fi active
- 2014-12-19 EP EP24178618.5A patent/EP4414035A3/en active Pending
- 2014-12-19 EP EP14830806.7A patent/EP3089749B1/en active Active
- 2014-12-19 CN CN201480073584.3A patent/CN105916504B/zh active Active
- 2014-12-19 TR TR2019/10866T patent/TR201910866T4/tr unknown
- 2014-12-19 PL PL14830806T patent/PL3089749T3/pl unknown
-
2019
- 2019-09-09 JP JP2019163672A patent/JP7160345B2/ja active Active
-
2020
- 2020-07-01 US US16/918,527 patent/US12214012B2/en active Active
-
2024
- 2024-12-24 US US19/000,820 patent/US20250127856A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503014A5 (enExample) | ||
| JP2019203035A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2018510132A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| CY1119886T1 (el) | Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους | |
| JP2015529225A5 (enExample) | ||
| JP2015212268A5 (enExample) | ||
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| JP2015517488A5 (enExample) | ||
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| JP2017537105A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| EP4609912A3 (en) | New use of a combination of sacubitril and valsartan | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| JP2018530578A5 (enExample) |